Conference
CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC)
Authors
Hotte SJ; Winquist E; Chi N; Ellard SL; Sridhar S; Emmenegger U; Salim M; Iqbal NN; Canil C; Kollmannsberger CK
Volume
30
Pagination
pp. 885-885
Publisher
OXFORD UNIV PRESS
Publication Date
October 2019
Name of conference
44th Congress of the European-Society-for-Medical-Oncology (ESMO)
Conference place
SPAIN, Barcelona
Conference start date
September 27, 2019
Conference end date
October 1, 2019
Conference proceedings
ANNALS OF ONCOLOGY
ISSN
0923-7534